Review

MicroRNAs and Uveal Melanoma: Understanding the Diverse Role of these Small Molecular Regulators

Karen Aughton 1,\*, Helen Kalirai 1,2 and Sarah E. Coupland 1,2,

1 Liverpool Ocular Oncology Research Group, Dept. of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK; kaughton@liverpool.ac.uk; hkalirai@liverpool.ac.uk; s.e.coupland@liverpool.ac.uk

2 Liverpool Clinical Laboratories, Liverpool University Hospital Foundation Trust, Liverpool, UK

**\*** Correspondence: kaughton@liverpool.ac.uk; Tel.: +44-151-7949120

Received: date; Accepted: date; Published: date

**Abstract:** Uveal melanoma (UM) is a rare tumour of the eye, characterised by a high propensity to metastasise in half of all patients, most frequently to the liver. Although there are effective treatment options for the primary tumour, once metastasis has occurred, prognosis is poor, with overall survival limited to months. Currently, there are no effective treatments for metastatic UM, despite the tumour having a well-defined signaling pathway to which many therapies have been directed. In an effort to develop novel treatment approaches, understanding the role of other signaling molecules, such as microRNAs, is fundamental. MicroRNAs (miRNAs) are small non-coding RNA molecules involved in posttranscriptional gene regulation, resulting in reduced target gene expression and subsequent protein translation. In UM, several dysregulated miRNAs have been proposed to play a functional role in UM disease progression, whilst others have been put forward as clinical biomarkers of high risk disease following isolation from blood, plasma and exosomes. Most recently, large dataset studies have identified promising prognostic miRNA signatures and panels. This review navigates the plethora of aberrant miRNAs disclosed so far in UM, and maps these to signaling pathways, which could be targeted in future therapies for the disseminated disease.

**Keywords:** uveal melanoma (UM); miRNA; biomarkers

1. Introduction

Uveal melanoma (UM), although the most common primary intraocular tumour, is a rare disease, affecting approximately 4-6 adults per million annually [1,2]. UM has a propensity for affecting those with light eye colour, fair skin, and an inability to tan, amongst other factors; and the incidence in Europe has been shown to follow a north-south downward gradient with a greater frequency of affected individuals residing in northern Scandinavian areas [3,4]. Ocular melanomas account for 3-5% of all melanomas, and the majority (approx. 85%) of these are located in the uvea, with the remainder arising in the conjunctiva [5-7]. UM are thought to arise from melanocytes in the uveal tract, comprising the iris, ciliary body, and choroid; with most UM occurring in the choroid (90%) [8].

Although treatment of the primary UM by radiotherapy, surgical resection or enucleation, is most often successful with little local recurrence, approximately 50% of patients will develop metastases for which there are no current effective therapies. The metastatic niche is most frequently the liver (90%), although other organs including bone, lung and skin can be affected [9]. Once metastatic UM is detected, the prognosis for the patient is poor leading to death occurring within months [9].

UM are characterised by a low mutational burden, with recurrent chromosomal losses and gains culminating in a relatively simple genetic landscape [10]. Historically, UM have been subdivided into those with low or high metastatic risk, based largely on somatic copy number alterations of chromosome 3 [11]. Tumours with a high metastatic risk have a loss of one copy of Chr 3, termed monosomy 3 (M3); and those at low risk have the normal two copies, termed disomy 3 (D3) [12]. Other genetic aberrations, including gains of Chr8q [11-13], and inactivating mutations of BRCA1 Associated Protein (*BAP1*) gene have been correlated to a high metastatic risk and hence poor outcome [14-20]. Mutually exclusive mutations in two other genes, eukaryotic translation initiation factor 1A (*EIF1AX*) and splicing factor 3 subunit 1 (*SF3B1*), have allowed further subdivision of the low metastatic risk D3 group, with *EIF1AX* mutations associated with non-metastasising tumours [19,21], whereas *SF3B1* mutations are associated with a delayed metastatic onset (intermediate risk) [10,22].

UM are initiated by a gain-of-function driver mutation in *GNAQ* or *GNA11* G-protein coupled receptors in almost 80% of cases [23-25], most frequently at the Q209 position and less frequently at the R183 position. This results in constitutive activation of the Gα downstream signaling cascade including activation of MAPK, PI3K-Akt-mTOR, and Hippo (including YAP-TAZ ) pathways [26-31]. A number of signaling cascade molecules, such as MEK (selumetinib [32-35], trametinib [36]), and PKC (AEB071 [37,38]), have been targeted by therapeutics, with little or no change in patient overall survival [39-41]. Additionally, immunotherapy treatments targeting, anti-CTLA-4 (ipilimumab [42]) and anti-PD-1 [43-45], have had low response rates; though combination trials with immunotherapy agents, HDAC inhibitors (entinostat) and radioembolization are currently ongoing [39,46-48].

It is, therefore, imperative to explore other avenues of potential dysregulation within the UM landscape. Aberrant miRNA expression, frequently observed in a myriad of cancers, is also reported in UM. The studies undertaken in UM include those investigating: a) the functional roles of specific miRNAs in cell lines and tumour samples [49,50]; b) the prognostic and diagnostic use of miRNAs, individually and in networks, from not only tissue samples but also from plasma and circulating exosomes [51,52]; and larger data-mining *in-*silico studies often utilizing and extrapolating the power of The Cancer Genome Analysis (TCGA) study [53-55]. However, at present there is no clear consensus as to which of the identified miRNAs should be targeted for use either as diagnostic biomarkers or as potential druggable targets. This review explores aberrant miRNA expression in UM and maps these to signaling pathways that appear to regulate UM growth and could be exploited as future drug targets.

2. miRNA Role in Cancer

miRNAs are small, non-coding sections of RNA, approximately 21-25 nucleotides in length, which regulate gene expression in a sequence-dependent manner [56,57]. The first miRNA, lin-4, was discovered almost 30 years ago in the nematode *C. elegans* by Ambros et al. 1993, who reported sequence complementarity between lin-4 and the 3’ untranslated region (UTR) of the lin-14 gene [58,59]. This was followed in 2000 by the discovery of a second miRNA, let-7, regarded as a heterochronic gene required for developmental timing [60], which importantly was shown to retain evolutionary conservation between species [61]. There are now estimated to be approximately 2600 fully annotated miRNAs identified in the human genome [62], which are predicted to regulate anywhere between 30-60% of human mRNAs [63-65]. These small miRNA molecules are involved in the posttranscriptional gene regulation of key cellular processes, including apoptosis, differentiation, proliferation and cell cycle. Each miRNA carries a conserved seed sequence that is complementary to a miRNA response element (MRE) on the 3’ UTR region of target mRNAs [66]. Binding of the miRNA to MRE results most commonly in reduced gene expression by inducing translational repression, and mRNA deadenylation and decapping [67,68]; gene upregulation has also been reported and may result from direct action of miRNA binding or indirectly by relieving miRNA gene repression [69,70]. It is estimated that a single miRNA can target multiple genes, and a single gene can contain many MREs and be targeted by multiple miRNAs [71]. Synergism of miRNA regulation has been implicated in disease, and in oncogenesis [72], and allows modulation of complex regulatory networks of gene expression.

Dysregulation of miRNAs is frequently documented in most tumour types, with miRNAs most commonly downregulated [73]. This can be attributed to genetic loss, epigenetic silencing, and defects in signaling pathways, resulting in reduced mature miRNA levels [74]. Studying miRNA in cancer is complicated, due to the diversity of tumours and cell lines; however, the ability to isolate miRNAs from cells, serum and plasma [75], means that they remain attractive molecules as biomarkers of both prognosis and diagnosis, therapeutic targets and epigenetic agents. The extensive capability of high throughput screening technologies and bioinformatic prediction analyses provide great tools for exploring the function and role of miRNAs; however, experimental validation will ultimately prove a miRNA’s worth.

3. miRNA Expression and Metastatic Risk in UM

The first insight into miRNA dysregulation in UM was provided by Worley et al. in 2008 using microarray technology, with a view to identifying a prognostic biomarker of metastatic risk [76]. Having previously observed that gene expression profiling allowed UM to be separated into distinct groups correlating with prognosis [77], Worley and co-workers noted that miRNA expression also clustered UM into two distinct prognostic groups according to metastatic risk. They reported six upregulated miRNAs that could accurately distinguish low metastatic risk class 1 UM and high metastatic risk class 2 UM, and in particular they highlighted let-7b and miR-199a as major discriminators of high metastatic risk class 2 UM [77]. . In a limited study by Radhakrishnan et al. the miRNA expression profiles of a single primary UM from a patient with metastatic disease were compared with that of a primary UM from a patient who had not developed metastatic disease [78]. Eleven miRNAs were identified that were present in the metastasising versus the non-metastasising primary UM [78]; none of these miRNAs were identified in more comprehensive expression studies analyzing metastatic risk[53,55,76] (Figure 1). .

Most recently, TCGA-UM study, which analysed 80 primary UM samples, identified four main miRNA clusters that were clearly associated with chromosome 3 status, metastatic risk and corresponding DNA methylation profile [55]. It was demonstrated that miR-199a-3p/5p and let-7b-5p were highly expressed in M3-UM miRNA cluster 3 [55], supporting the data of Worley et al. [76]. In addition, M3-UM expressed lower levels of miRNAs located on chromosome 3 [55]. The wealth of information provided by the TCGA-UM study has allowed for larger data-mining *in-silico* studies often using these data, and some of these are discussed later in this review.

Smit et al. 2018 combined *in-house* microarray miRNA expression data, with data-mining of TCGA mRNA dataset for predicted gene targets [53]. Data from 26 primary UM samples subdivided into metastatic risk subgroups on the basis of chromosome 3 status and mutational sequencing for *EIF1AX* and *SF3B1* (7 low risk, 12 intermediate risk, 7 high risk) were analysed for differentially expressed miRNAs; miR-17-5p, miR-21-5p and miR-151a-3p were differentially expressed between high risk and low/intermediate risk groups [53]. Following gene target association using the TCGA-UM dataset (106 genes predicted), bioinformatics pathway analysis software revealed that the miRNAs interact with genes involved in cancer-related pathways including cell cycle regulation pathways, EIF2 and EGF signaling [53].

A similar approach was taken by Wróblewska et al. 2020, but this time combining TCGA miRNA data with miRNA validation in patient samples [79]. They identified a panel of 15 miRNAs differentially expressed between four TCGA-UM study patients (stage IIA tumours and without metastatic disease)and versus four TCGA-UM patients (stage IV with metastatic disease). Further validation of six of the miRNAs in 28 primary UM with no evidence of metastasis and 18 primary UM where metastatic disease had developed at the time of follow-up, demonstrated that miR-592, miR-346 and miR-1247 were significantly increased, and that miR-506 and miR-513c were significantly decreased in the metastatic subgroup [79].

In contrast to the above studies, Larsen et al. 2014 found no association of miRNA expression with metastasis and survival in 26 primary UM patients, 15 of whom had died of metastatic disease [80].

To examine the commonality of the miRNAs reported to be associated with increased metastatic risk, we compared three studies that examined miRNA expression *de novo* in large clinically well-defined UM sample sets [53,55,76]. Interestingly, little overlap was noted for the miRNAs identified by each study (Figure 1), with similarities only being observed for Let-7b, miR-199a, miR-143, miR-155, and miR-21 (upregulated miRNAs), and only for miR-181a (downregulated miRNAs). Differences in study design, tissue sample classifications, and miRNA detection systems (microarray vs RNA-Seq) may all contribute to the differences in miRNAs reported as significantly associated with an increased metastatic risk in UM. However, this lack of commonality between studies emphasizes the need for functional validation of any proposed miRNAs as biomarkers in UM moving forward.

4. The Functional Role of miRNAs in UM

When considering the functional role of miRNAs in UM, it is generally accepted that miRNAs will have either a tumour-suppressing or tumour-promoting role, and miRNA dysregulation is reflected by the expression levels of the miRNA in the tumour. An increasing number of studies are beginning to define the role of many different miRNAs in UM samples and cell lines, predominantly using *in vitro* models, although some data stem from *in vivo* models. miRNA targets have been derived from *in-house* microarray expression data, or identified from studies in other cancer types, in particular skin melanoma, which may hold relevance to the UM signaling pathway.

Generally, the format of these previous studies addresses the expression of the miRNA in UM cell lines and tissue, compared with melanocytes and “normal” (often adjacent) tissue, respectively. This is subsequently followed by cell proliferation-, invasion-, migration-, and cell cycle analyses with or without transfection of miRNA mimics and inhibitors. Bioinformatic predictions using miRNA databases are employed to determine downstream targets, which are confirmed using luciferase assays. Additional analyses include target gene expression levels *in situ,* and in response to miRNA mimics or inhibitors, again correlating this with effects on cell growth, invasion, and migration to confirm the miRNA-gene relationship. Whilst these studies have provided a large amount of information, certain limitations exist. For example, the UM cell lines used within the majority of studies are restricted to two or three of those that are less well-characterised in the literature [81,82]. There are a large number of genetically characterised UM cell lines available, which better represent the disease and should be considered for use as a panel, to gain a more complete understanding of the target miRNA function. In particular, the use of UM cell lines with loss of nuclear BAP1 expression, and/or chromosome 3 loss would be beneficial to understand their role in metastatic progression [83].

Nevertheless, the functional studies undertaken in UM examine both oncogenic and tumour suppressor miRNAs, providing key data for further evaluation. Oncogenic miRNAs downregulate tumour suppressor gene transcription, and are listed in Table 1. On the other hand, downregulation of tumour suppressor miRNAs results in UM progression by allowing their target oncogene to be subsequently upregulated. Tumour suppressor miRNAs are listed in Table 2.

4.1. miRNA as oncogenes in UM

Oncogenic miRNAs in UM include the miR-181 family, comprising four miRNAs (miR-181a/b/c/d), which are transcribed from different gene loci. In UM, it was found that all miR-181 family members were highly homologous and able to regulate the effector gene *CTDSPL*, a phosphatase-like tumour suppressor gene that dephosphorylates Rb1 and regulates the RNA polymerase II transcription machinery [50]. All members of the miR-181 family were significantly overexpressed in UM and cell lines (including 92.1 cells); however, miR-181b was highlighted as the most effective regulator of the downstream gene *CTDSPL*. miR-181b repression of *CTDSPL* resulted in Rb protein phosphorylation and E2F1 transcription factor protein expression, with subsequent cell cycle progression [50].

Other oncogenic miRNAs include miR-155 [84], miR-20a [85], and miR-216a-5p, which targets the hexokinase 2 (*HK2*) gene involved in cell metabolism [86]. Interestingly, two oncogenic miRNAs have been shown to target *PTEN* in UM, namely miR-454 [87] and miR-367 [88]. Both miRNAs were upregulated in UM cell lines and samples, and had significant effects on promoting cell proliferation, cell cycle, migration and invasion by directly targeting *PTEN*. Individually, miR-454 has been reported to be involved in hepatic stellate cell activation [89], and both miRNAs are involved in TGFβ signaling pathways via the SMAD family of genes [88,90]. These studies highlight that multiple miRNAs are able to target a single gene, and also that data from ‘single gene-single target’ studies must be viewed in a wider context when trying to determine the overall miRNA landscape of UM.

**Table 1.** Upregulated oncogenic miRNAs in UM.

|  |  |  |  |
| --- | --- | --- | --- |
| **miRNA** | **Target** | **Functions** | **Reference** |
| miR-182 | *MITF, BCL2, CyclinD2* | Proliferation, cell cycle, colony formation, migration, invasion. Doxorubicin sensitivity. | [91] |
| miR-454 | *PTEN* | Proliferation, colony formation, invasion, cell cycle | [87] |
| miR-20a | *-* | Proliferation, invasion, migration | [85] |
| miR-124(lnHOXA11-AS)**\*** | *P21* | Proliferation, invasion, apoptosis | [92] |
| miR-367 | *PTEN* | Proliferation, cell cycle, migration | [88] |
| miR-155 | *NDFIP1* | Proliferation, invasion | [84] |
| miR-181 | *CTDSPL* | Cell cycle | [50] |
| miR-216a-5p | *HK2* | Glycolysis, lactate production, ATP generation, ECAR, OCR | [86] |
| miR-652 | *HOXA9* | Proliferation, migration | [93] |

4.2. miRNA as tumour suppressors in UM

miRNAs considered to be tumour suppressors in UM include members of the miR-34 family, to which multiple manuscripts are dedicated. The miR-34 family been implicated in multiple solid tumour types (e.g. colorectal-, breast-, lung and liver carcinomas, as well as osteosarcomas [94]). In UM miR-34a/b/c [49,95] are all downregulated and predicted to target c-Met directly, with other indirect targets, including p53, pAkt, and numerous cell cycle proteins. Transfection of miR-34a/b/c resulted in target protein downregulation and reduction in cell proliferation, invasion and migration [49,95]. Follow on studies of miR-34a have reported its involvement in the regulation of LGR4, a universal tumour promoter, and downstream epithelial to mesenchymal transition proteins such as E-cadherin, N-cadherin, vimentin, SNAIL and MMP2 [96]; such that downregulation of miR-34a, lends to activation of epithelial signaling [96].

Since the identification of the important role of the miR-34 family in UM, the first tumour-targeted miRNA drug, MRX34, has been used in a phase I clinical trial based on miR-34a [94]. Unfortunately, MRX34 was withdrawn due to immune-related adverse events; however, it highlights the advances being made in this field, and the possibility of epigenetic modulating drugs being used in the future treatment of disseminated UM. Finally, miR-34a response elements (MREs) have been used to help direct a TRAIL-expressing adenoviral vector in UM cell lines and UM xenografts with high anti-tumour activity, thereby helping to improve specificity of drugs [97].

Most recently, Amaro et al. 2020, investigated the regulation of metastatic genes *ADAM10* and *c-Met* by miR-122 and miR-144 [98]. In this study, they confirmed downregulation of both miRNAs by microarray analysis in primary UM samples and cell lines, and analysed the TCGA database (see below section) to validate their findings. Further analysis showed that overexpression of miR-122 and miR-144 reduced ADAM10 and c-Met protein expression resulting in reduced proliferation, migration and cell cycle progression [98].

**Table 2.** Downregulated tumour suppressor miRNAs in UM.

|  |  |  |  |
| --- | --- | --- | --- |
| **miRNA** | **Target** | **Functions** | **Reference** |
| miR-34a | *c-Met* | Proliferation, migration | [49] |
| miR-137 | *MITF, CDK6* | Proliferation, cell cycle | [99] |
| miR-34b/c | *c-Met* | Proliferation, migration, cell cycle | [95] |
| miR-9 | *NF-κB1, MMP2/9, VEGFA* | Proliferation, migration, invasion | [100] |
| miR-124a | *EZHZ, CDK4, CDK6, CCND2* | Proliferation, migration, invasion, colony formation, cell cycleEpigenetically regulated - methylation and histone modification. | [101] |
| miR-145 | *IRS-1* | Proliferation, cell cycle, apoptosis | [102] |
| Let-7b | *CyclinD1* | Radiosensitivity, cell cycle, proliferation | [103] |
| miR-144 | *c-Met* | Proliferation, invasion | [104] |
| miR-137 | *SRC1, 2, 3* | Proliferation, cell viability | [105] |
| miR-140 (lnc MALAT1)**\*** | *Slug, ADAM10* | Proliferation, colony formation, migration, invasion | [106] |
| miR-224-5p (lnc FTH1P3)**\*** | *Rac1, Fizzled 5* | Proliferation, migration, cell cycle | [107] |
| miR-224-5p | *PIK3R3-AKT3* | Proliferation, invasion, migration | [108] |
| miR-142-3p | *CDC25C, TGFβ1R1,**GNAQ, WASL, RAC1* | Proliferation, invasion, migration, cell cycle | [109] |
| miR-34a | *LGR4, E-Cad, N-Cad, Vim, Snail, MMP2* | Migration, invasion | [96] |
| miR-17-3p(lncPVT1)**\*** | *MDM2* | Cell viability, invasion, migration, apoptosis, cell cycle, tumour volume | [110] |
| miR-145/205 | *NRP1* | Proliferation, invasion | [111] |
| miR-122/144 | *ADAM10/c-Met* | Proliferation, migration, cell cycle | [98] |

4.3. Alternative mechanisms of miRNA regulation in UM

Regulation of miRNA by other epigenetic molecules, such as long-noncoding RNAs (lncRNA), have also been shown to play a role in UM progression. Oncogenic miR-124 is regulated by lnHOXA11-AS, and targets the cyclin dependent kinase inhibitor P21 [92]. In addition, the tumour suppressor miRNA-224-5p is regulated by lncFTH1P3, targeting Rac1 and Fizzled 5 [107], whilst miR-17-3p is regulated by lncPVT1, targeting MDM2 [110] (these are denoted in Tables 1 and 2 by an asterix (**\***)). These provide evidence that epigenetic regulation of miRNAs by other mechanisms, adds an additional layer in the complexity of signaling pathway regulation.

5. miRNA as Clinical Biomarkers of UM

When undertaking any miRNA scientific study, the ultimate goal will either be a functional outcome for potential epigenetic modification or drug targeting, or as a biomarker for prognosis and diagnosis. In UM, chromosomal mutations and genetic aberrations in the primary tumour can predict with relatively high accuracy whether a UM has a low or high risk of metastasis. When incorporated with other prognostic parameters – i.e. clinical and histological characteristics-, expected survival for an individual patient can be predicted [112]. This is a robust approach that has been translated into the clinic; however, it requires tissue samples obtained by fine needle biopsies, tumour resections or enucleations [113]. Therefore, there is a huge appeal in being able to detect dysregulated miRNAs from plasma and serum samples of UM patients.

5.1. Blood biomarkers in UM

Triozzi et al. in 2012 looked into monitoring anti-angiogenic treatments in UM by detecting miRNAs in blood and associating them with circulating endothelial cells (CEC) and angiogenic proteins [114]. Blood samples from patients on an adjuvant therapy trial receiving dacarbazine followed by interferon-alfa-2b were used to detect the presence of a panel of 9 plasma miRNAs. Of these miRNAs, miR-199a and miR-106a, were shown to correlate with CEC pre-therapy. Further, the plasma levels of these miRNAs and those of miR216 and miR16 were shown to change following treatment with interferon-alfa-2b, but not dacarbazine. Follow on studies from this trial subsequently correlated circulating plasma miRNA levels with metastasis [115]. In a study of six UM patients, miR-20a, miR-125b, miR-146a, miR-155, miR-181a and miR-223 plasma levels were all shown to be increased at time of diagnosis of primary UM, compared with healthy controls (no ocular disease) [115]. At the time of metastasis, miR-20a, miR-125b, miR-146a, miR-155 and miR-223 plasma levels had increased, and miR-181a decreased [115]. In serum, samples from UM patients undergoing enucleation, eight differentially expressed miRNAs were identified (miR-146a, miR-523 upregulated; miR-19a, miR-30d, miR-127, miR-451, miR-518f, miR-1274B downregulated) compared with normal controls [116]. Further, miR-146a was validated in FFPE UM samples and confirmed to be upregulated [116]. Finally, a study comparing plasma and UM sample miRNA expression, confirmed three miRNAs to be significantly elevated and which were previously detected as increased in tissue microarrays of M3 UM compared with D3 tumours – namely, miR-92b, miR-199-5p, and miR-223 [51].

Most recently, Stark et al. 2019, conducted a cross-sectional, multicentre study to determine whether circulating miRNAs in serum could help distinguish benign uveal nevi from UM [117], one of the remaining clinical diagnostic difficulties. Using a panel of 17 miRNAs, the authors discovered that miR-16, miR-145, miR-146a, miR-204, miR-211 and miR-363-3p, all showed significant differences between uveal nevi and primary/metastatic UM [117]. In addition, miR-211 was able to distinguish metastatic UM from primary UM. When analysing the six miRNA distinguishers as a group, by assigning diagnostic scores to the data and using multiple testing statistics with defined cut-offs that allowed categorisation of expression values as positive or negative for UM, it was revealed that when ≥4 miRNAs reached or exceeded their cut-off, that they could successfully distinguish uveal nevi from UM [117].

5.1. Exosomal biomarkers in UM

Other sources of miRNAs that have been studied are those present in exosomes. Exosomes are small (30- to 100-nm), membrane bound vesicles released by eukaryotic cells that carry a range of bioactive molecules including miRNA [118]. Cancer cells have been reported to aberrantly release exosomes in order to communicate with their environment, thereby promoting cellular processes such as proliferation, angiogenesis and the preparation of the pre-metastatic niche [118].

In UM, exosomes were successfully isolated from the liver perfusate of patients with metastatic disease undergoing isolated hepatic perfusion [52]. Melan-A positive exosomes were found to be present in greater numbers in patients with metastatic UM than those isolated from healthy peripheral blood plasma controls. Exosomes derived from metastatic UM in the liver shared distinct miRNA clusters, which were different from exosomes isolated from tumour cell cultures, however these did not include cultures from UM cells [52]. Another study examined exosomes isolated from the vitreous humor (VH) with miRNA profiles of serum and VH from UM patients and healthy controls, demonstrating that VH exosome miRNA and VH miRNA from UM patients shared similar expression profiles, but were distinct from miRNAs isolated from serum of the same patients [119]. Dysregulated miRNAs in VH and vitreous exosomes included upregulated miR-21, miR-34a, and miR-146a, of which miR-146a was also upregulated in UM patient serum and exosomes [119].

6. *In-silico* Predictive Studies of miRNA Biomarkers in UM

The publication of the TCGA-UM study, which applied high-throughput sequencing of 80 primary UM samples to establish a large publicly-available dataset of genomic data [55], has enabled extensive *in-silico* datamining by various groups. The output of these studies identifies a variety of miRNAs, sometimes with commonality between studies, but most often identifying novel miRNAs that are cited as predictive biomarkers of high risk UM. As mentioned above, the lack of concordance between studies can be attributed to differences in study design and data handling, and highlight the importance in further validating these miRNAs as predictive biomarkers. However, it is encouraging that there are multiple avenues with which to secure successful predictive biomarkers for future clinical use.

Falzone et al. 2019 published a study looking for prognostic miRNA biomarkers by stratifying UM patients into two groups, firstly by tumour stage (high grade vs low grade), and subsequently by survival status (dead vs alive) [54]. From this they identified seven dysregulated miRNAs in common between the groups, including five downregulated (miR-514a-3p, miR-508-3p, miR-509-3-5p, miR-513c-5p, miR-513a-5p) and two upregulated (miR-592, miR-199a-5p) [54]. Further analysis revealed that the most highly dysregulated miRNAs in the high grade versus low grade UM groups, which correlated with overall survival, were miR-506-514 cluster, miR-592 and miR-199a-5p [54]. Gene ontology analysis showed that genes associated with miRNAs highlighted in this study include those involved in the MAPK1 and PI3K-Akt pathways, known components of UM signaling, as mentioned above.

Other prognostic signatures identified include a nine-miRNA signature derived from dividing the TCGA-UM dataset randomly into a training and test set (40 per group) and using Cox proportional hazard regression model and receiver operating curves (ROC) to confirm signature accuracy [120]. The nine miRNA signature includes upregulated levels of miR-195, miR-224, miR-365a, miR-365b, miR-452, miR-4709, miR-7702 associated with increased metastatic risk, and miR-513c, and miR-873 with high expression that were associated with reduced metastatic risk; when combined this signature was able to accurately distinguish UM patients at high and low metastatic risk [120].

7. Conclusion

In summary, a large number of varied miRNA studies have been undertaken to help define the miRNA expression profiles in UM, the functional role of some of these miRNAs, and their predicted targets for use as future prognostic biomarkers or drug targets for epigenetic/small molecule agents.

The range of miRNAs with assumed importance in UM progression/signalling is vast; however, some commonalities can be drawn from the data, and an overview is shown in Figure 2. Within this Figure, miRNAs potentially associated with UM progression/metastatic risk and those already examined in functional studies are listed; miRNAs reported across multiple studies are highlighted in bold, and include those that are upregulated (miR-20a, miR-124, miR-155, miR-224, Let-7b, miR-142, miR-199) as well as those that are downregulated (miR-181a and miR-211). Bioinformatic pathway analyses combined with functional analyses indicate that cell cycle- and translation pathway dysregulation are significant in UM; and MAPK and PI3K-Akt signaling appear to be promising targets of multiple dysregulated miRNAs.

Whilst these studies may highlight particular miRNAs that are involved in UM development and progression, it is important to emphasize that these studies need to be considered together, in order to fully understand the complex regulatory signaling of miRNAs in UM. Functional analyses undertaken to date tend to be stand-alone observations, and do not address the miRNA networks known to be involved in cancer. On the other hand, bioinformatic analyses are often only predictive, and require functional validation in an *in-vitro* setting. Experimental caveats also have to be considered, including the choice of UM cell lines and their genetic diversity. Often the genetic and chromosomal aberration data of the samples examined are absent in the studies, and therefore their observations/conclusions may be over-simplified. Additionally, future studies may take advantage of emerging three-dimensional pre-clinical models in a range of genetically diverse UM cell lines, exploring the signaling role of miRNAs in a more clinically relevant setting [121].

This review has attempted to summarise the main findings of these numerous studies, emphasising where overlap occurs and suggesting a ‘roadmap’ to direct future studies of miRNAs in UM.

**Conflicts of Interest:** The authors declare no conflict of interest.

References

1. Damato, B. Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture. *Eye (Lond)* **2012**, *26*, 1157-1172, doi:10.1038/eye.2012.126.

2. Jager, M.J.; Shields, C.L.; Cebulla, C.M.; Abdel-Rahman, M.H.; Grossniklaus, H.E.; Stern, M.H.; Carvajal, R.D.; Belfort, R.N.; Jia, R.; Shields, J.A., et al. Uveal melanoma. *Nat Rev Dis Primers* **2020**, *6*, 24, doi:10.1038/s41572-020-0158-0.

3. Virgili, G.; Gatta, G.; Ciccolallo, L.; Capocaccia, R.; Biggeri, A.; Crocetti, E.; Lutz, J.M.; Paci, E.; Group, E.W. Incidence of uveal melanoma in Europe. *Ophthalmology* **2007**, *114*, 2309-2315, doi:10.1016/j.ophtha.2007.01.032.

4. Kaliki, S.; Shields, C.L. Uveal melanoma: relatively rare but deadly cancer. *Eye (Lond)* **2017**, *31*, 241-257, doi:10.1038/eye.2016.275.

5. Singh, A.D.; Turell, M.E.; Topham, A.K. Uveal melanoma: trends in incidence, treatment, and survival. *Ophthalmology* **2011**, *118*, 1881-1885, doi:10.1016/j.ophtha.2011.01.040.

6. Chang, A.E.; Karnell, L.H.; Menck, H.R. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society. *Cancer* **1998**, *83*, 1664-1678, doi:10.1002/(sici)1097-0142(19981015)83:8<1664::aid-cncr23>3.0.co;2-g.

7. Jovanovic, P.; Mihajlovic, M.; Djordjevic-Jocic, J.; Vlajkovic, S.; Cekic, S.; Stefanovic, V. Ocular melanoma: an overview of the current status. *Int J Clin Exp Pathol* **2013**, *6*, 1230-1244.

8. Damato, E.M.; Damato, B.E. Detection and time to treatment of uveal melanoma in the United Kingdom: an evaluation of 2,384 patients. *Ophthalmology* **2012**, *119*, 1582-1589, doi:10.1016/j.ophtha.2012.01.048.

9. Damato, B.; Eleuteri, A.; Taktak, A.F.; Coupland, S.E. Estimating prognosis for survival after treatment of choroidal melanoma. *Prog Retin Eye Res* **2011**, *30*, 285-295, doi:10.1016/j.preteyeres.2011.05.003.

10. Furney, S.J.; Pedersen, M.; Gentien, D.; Dumont, A.G.; Rapinat, A.; Desjardins, L.; Turajlic, S.; Piperno-Neumann, S.; de la Grange, P.; Roman-Roman, S., et al. SF3B1 mutations are associated with alternative splicing in uveal melanoma. *Cancer Discov* **2013**, *3*, 1122-1129, doi:10.1158/2159-8290.CD-13-0330.

11. Thornton, S.; Coupland, S.E.; Olohan, L.; Sibbring, J.S.; Kenny, J.G.; Hertz-Fowler, C.; Liu, X.; Haldenby, S.; Heimann, H.; Hussain, R., et al. Targeted Next-Generation Sequencing of 117 Routine Clinical Samples Provides Further Insights into the Molecular Landscape of Uveal Melanoma. *Cancers (Basel)* **2020**, *12*, doi:10.3390/cancers12041039.

12. Damato, B.; Dopierala, J.; Klaasen, A.; van Dijk, M.; Sibbring, J.; Coupland, S.E. Multiplex ligation-dependent probe amplification of uveal melanoma: correlation with metastatic death. *Invest Ophthalmol Vis Sci* **2009**, *50*, 3048-3055, doi:10.1167/iovs.08-3165.

13. Versluis, M.; de Lange, M.J.; van Pelt, S.I.; Ruivenkamp, C.A.; Kroes, W.G.; Cao, J.; Jager, M.J.; Luyten, G.P.; van der Velden, P.A. Digital PCR validates 8q dosage as prognostic tool in uveal melanoma. *PLoS One* **2015**, *10*, e0116371, doi:10.1371/journal.pone.0116371.

14. Kalirai, H.; Dodson, A.; Faqir, S.; Damato, B.E.; Coupland, S.E. Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing. *Br J Cancer* **2014**, *111*, 1373-1380, doi:10.1038/bjc.2014.417.

15. Koopmans, A.E.; Verdijk, R.M.; Brouwer, R.W.; van den Bosch, T.P.; van den Berg, M.M.; Vaarwater, J.; Kockx, C.E.; Paridaens, D.; Naus, N.C.; Nellist, M., et al. Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma. *Mod Pathol* **2014**, *27*, 1321-1330, doi:10.1038/modpathol.2014.43.

16. Harbour, J.W.; Onken, M.D.; Roberson, E.D.; Duan, S.; Cao, L.; Worley, L.A.; Council, M.L.; Matatall, K.A.; Helms, C.; Bowcock, A.M. Frequent mutation of BAP1 in metastasizing uveal melanomas. *Science* **2010**, *330*, 1410-1413, doi:10.1126/science.1194472.

17. van de Nes, J.A.; Nelles, J.; Kreis, S.; Metz, C.H.; Hager, T.; Lohmann, D.R.; Zeschnigk, M. Comparing the Prognostic Value of BAP1 Mutation Pattern, Chromosome 3 Status, and BAP1 Immunohistochemistry in Uveal Melanoma. *Am J Surg Pathol* **2016**, *40*, 796-805, doi:10.1097/PAS.0000000000000645.

18. Thornton, S.; Kalirai, H.; Aughton, K.; Coupland, S.E. Unpacking the genetic etiology of uveal melanoma. *Expert Review of Ophthalmology* **2020**, 10.1080/17469899.2020.1785872, 1-10, doi:10.1080/17469899.2020.1785872.

19. Smit, K.N.; Jager, M.J.; de Klein, A.; Kili, E. Uveal melanoma: Towards a molecular understanding. *Prog Retin Eye Res* **2020**, *75*, 100800, doi:10.1016/j.preteyeres.2019.100800.

20. Farquhar, N.; Thornton, S.; Coupland, S.E.; Coulson, J.M.; Sacco, J.J.; Krishna, Y.; Heimann, H.; Taktak, A.; Cebulla, C.M.; Abdel-Rahman, M.H., et al. Patterns of BAP1 protein expression provide insights into prognostic significance and the biology of uveal melanoma. *J Pathol Clin Res* **2018**, *4*, 26-38, doi:10.1002/cjp2.86.

21. Martin, M.; Masshofer, L.; Temming, P.; Rahmann, S.; Metz, C.; Bornfeld, N.; van de Nes, J.; Klein-Hitpass, L.; Hinnebusch, A.G.; Horsthemke, B., et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. *Nat Genet* **2013**, *45*, 933-936, doi:10.1038/ng.2674.

22. Yavuzyigitoglu, S.; Koopmans, A.E.; Verdijk, R.M.; Vaarwater, J.; Eussen, B.; van Bodegom, A.; Paridaens, D.; Kilic, E.; de Klein, A.; Rotterdam Ocular Melanoma Study, G. Uveal Melanomas with SF3B1 Mutations: A Distinct Subclass Associated with Late-Onset Metastases. *Ophthalmology* **2016**, *123*, 1118-1128, doi:10.1016/j.ophtha.2016.01.023.

23. Van Raamsdonk, C.D.; Griewank, K.G.; Crosby, M.B.; Garrido, M.C.; Vemula, S.; Wiesner, T.; Obenauf, A.C.; Wackernagel, W.; Green, G.; Bouvier, N., et al. Mutations in GNA11 in uveal melanoma. *N Engl J Med* **2010**, *363*, 2191-2199, doi:10.1056/NEJMoa1000584.

24. Onken, M.D.; Worley, L.A.; Long, M.D.; Duan, S.; Council, M.L.; Bowcock, A.M.; Harbour, J.W. Oncogenic mutations in GNAQ occur early in uveal melanoma. *Invest Ophthalmol Vis Sci* **2008**, *49*, 5230-5234, doi:10.1167/iovs.08-2145.

25. Van Raamsdonk, C.D.; Bezrookove, V.; Green, G.; Bauer, J.; Gaugler, L.; O'Brien, J.M.; Simpson, E.M.; Barsh, G.S.; Bastian, B.C. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. *Nature* **2009**, *457*, 599-602, doi:10.1038/nature07586.

26. Patel, M.; Smyth, E.; Chapman, P.B.; Wolchok, J.D.; Schwartz, G.K.; Abramson, D.H.; Carvajal, R.D. Therapeutic implications of the emerging molecular biology of uveal melanoma. *Clin Cancer Res* **2011**, *17*, 2087-2100, doi:10.1158/1078-0432.CCR-10-3169.

27. Griewank, K.G.; van de Nes, J.; Schilling, B.; Moll, I.; Sucker, A.; Kakavand, H.; Haydu, L.E.; Asher, M.; Zimmer, L.; Hillen, U., et al. Genetic and clinico-pathologic analysis of metastatic uveal melanoma. *Mod Pathol* **2014**, *27*, 175-183, doi:10.1038/modpathol.2013.138.

28. Feng, X.; Degese, M.S.; Iglesias-Bartolome, R.; Vaque, J.P.; Molinolo, A.A.; Rodrigues, M.; Zaidi, M.R.; Ksander, B.R.; Merlino, G.; Sodhi, A., et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. *Cancer Cell* **2014**, *25*, 831-845, doi:10.1016/j.ccr.2014.04.016.

29. Shoushtari, A.N.; Carvajal, R.D. GNAQ and GNA11 mutations in uveal melanoma. *Melanoma Res* **2014**, *24*, 525-534, doi:10.1097/CMR.0000000000000121.

30. Croce, M.; Ferrini, S.; Pfeffer, U.; Gangemi, R. Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives. *Cancers (Basel)* **2019**, *11*, doi:10.3390/cancers11060846.

31. Park, J.J.; Diefenbach, R.J.; Joshua, A.M.; Kefford, R.F.; Carlino, M.S.; Rizos, H. Oncogenic signaling in uveal melanoma. *Pigment Cell Melanoma Res* **2018**, *31*, 661-672, doi:10.1111/pcmr.12708.

32. Carvajal, R.D.; Sosman, J.A.; Quevedo, J.F.; Milhem, M.M.; Joshua, A.M.; Kudchadkar, R.R.; Linette, G.P.; Gajewski, T.F.; Lutzky, J.; Lawson, D.H., et al. Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. *JAMA* **2014**, *311*, 2397-2405, doi:10.1001/jama.2014.6096.

33. Carvajal, R.D.; Piperno-Neumann, S.; Kapiteijn, E.; Chapman, P.B.; Frank, S.; Joshua, A.M.; Piulats, J.M.; Wolter, P.; Cocquyt, V.; Chmielowski, B., et al. Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT). *J Clin Oncol* **2018**, *36*, 1232-1239, doi:10.1200/JCO.2017.74.1090.

34. Carvajal, R.D.; Schwartz, G.K.; Mann, H.; Smith, I.; Nathan, P.D. Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT). *BMC Cancer* **2015**, *15*, 467, doi:10.1186/s12885-015-1470-z.

35. Komatsubara, K.M.; Manson, D.K.; Carvajal, R.D. Selumetinib for the treatment of metastatic uveal melanoma: past and future perspectives. *Future Oncol* **2016**, *12*, 1331-1344, doi:10.2217/fon-2015-0075.

36. Falchook, G.S.; Lewis, K.D.; Infante, J.R.; Gordon, M.S.; Vogelzang, N.J.; DeMarini, D.J.; Sun, P.; Moy, C.; Szabo, S.A.; Roadcap, L.T., et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. *Lancet Oncol* **2012**, *13*, 782-789, doi:10.1016/S1470-2045(12)70269-3.

37. Piperno-Neumann, S.; Larkin, J.; Carvajal, R.D.; Luke, J.J.; Schwartz, G.K.; Hodi, F.S.; Sablin, M.P.; Shoushtari, A.N.; Szpakowski, S.; Chowdhury, N.R., et al. Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071. *Mol Cancer Ther* **2020**, *19*, 1031-1039, doi:10.1158/1535-7163.MCT-19-0098.

38. Carita, G.; Frisch-Dit-Leitz, E.; Dahmani, A.; Raymondie, C.; Cassoux, N.; Piperno-Neumann, S.; Nemati, F.; Laurent, C.; De Koning, L.; Halilovic, E., et al. Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma. *Oncotarget* **2016**, *7*, 33542-33556, doi:10.18632/oncotarget.9552.

39. Yang, J.; Manson, D.K.; Marr, B.P.; Carvajal, R.D. Treatment of uveal melanoma: where are we now? *Ther Adv Med Oncol* **2018**, *10*, 1758834018757175, doi:10.1177/1758834018757175.

40. Steeb, T.; Wessely, A.; Ruzicka, T.; Heppt, M.V.; Berking, C. How to MEK the best of uveal melanoma: A systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma. *Eur J Cancer* **2018**, *103*, 41-51, doi:10.1016/j.ejca.2018.08.005.

41. Chua, V.; Lapadula, D.; Randolph, C.; Benovic, J.L.; Wedegaertner, P.B.; Aplin, A.E. Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma. *Mol Cancer Res* **2017**, *15*, 501-506, doi:10.1158/1541-7786.MCR-17-0007.

42. Zimmer, L.; Vaubel, J.; Mohr, P.; Hauschild, A.; Utikal, J.; Simon, J.; Garbe, C.; Herbst, R.; Enk, A.; Kampgen, E., et al. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma. *PLoS One* **2015**, *10*, e0118564, doi:10.1371/journal.pone.0118564.

43. Algazi, A.P.; Tsai, K.K.; Shoushtari, A.N.; Munhoz, R.R.; Eroglu, Z.; Piulats, J.M.; Ott, P.A.; Johnson, D.B.; Hwang, J.; Daud, A.I., et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. *Cancer* **2016**, *122*, 3344-3353, doi:10.1002/cncr.30258.

44. Heppt, M.V.; Heinzerling, L.; Kahler, K.C.; Forschner, A.; Kirchberger, M.C.; Loquai, C.; Meissner, M.; Meier, F.; Terheyden, P.; Schell, B., et al. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition. *Eur J Cancer* **2017**, *82*, 56-65, doi:10.1016/j.ejca.2017.05.038.

45. Heppt, M.V.; Steeb, T.; Schlager, J.G.; Rosumeck, S.; Dressler, C.; Ruzicka, T.; Nast, A.; Berking, C. Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review. *Cancer Treat Rev* **2017**, *60*, 44-52, doi:10.1016/j.ctrv.2017.08.009.

46. Schank, T.E.; Hassel, J.C. Immunotherapies for the Treatment of Uveal Melanoma-History and Future. *Cancers (Basel)* **2019**, *11*, doi:10.3390/cancers11081048.

47. Heijkants, R.; Willekens, K.; Schoonderwoerd, M.; Teunisse, A.; Nieveen, M.; Radaelli, E.; Hawinkels, L.; Marine, J.C.; Jochemsen, A. Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma. *Oncotarget* **2018**, *9*, 6174-6187, doi:10.18632/oncotarget.23485.

48. Vivet-Noguer, R.; Tarin, M.; Roman-Roman, S.; Alsafadi, S. Emerging Therapeutic Opportunities Based on Current Knowledge of Uveal Melanoma Biology. *Cancers (Basel)* **2019**, *11*, doi:10.3390/cancers11071019.

49. Yan, D.; Zhou, X.; Chen, X.; Hu, D.N.; Dong, X.D.; Wang, J.; Lu, F.; Tu, L.; Qu, J. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met. *Invest Ophthalmol Vis Sci* **2009**, *50*, 1559-1565, doi:10.1167/iovs.08-2681.

50. Zhang, L.; He, X.; Li, F.; Pan, H.; Huang, X.; Wen, X.; Zhang, H.; Li, B.; Ge, S.; Xu, X., et al. The miR-181 family promotes cell cycle by targeting CTDSPL, a phosphatase-like tumor suppressor in uveal melanoma. *J Exp Clin Cancer Res* **2018**, *37*, 15, doi:10.1186/s13046-018-0679-5.

51. Triozzi, P.L.; Achberger, S.; Aldrich, W.; Crabb, J.W.; Saunthararajah, Y.; Singh, A.D. Association of tumor and plasma microRNA expression with tumor monosomy-3 in patients with uveal melanoma. *Clin Epigenetics* **2016**, *8*, 80, doi:10.1186/s13148-016-0243-0.

52. Eldh, M.; Olofsson Bagge, R.; Lasser, C.; Svanvik, J.; Sjostrand, M.; Mattsson, J.; Lindner, P.; Choi, D.S.; Gho, Y.S.; Lotvall, J. MicroRNA in exosomes isolated directly from the liver circulation in patients with metastatic uveal melanoma. *BMC Cancer* **2014**, *14*, 962, doi:10.1186/1471-2407-14-962.

53. Smit, K.N.; Chang, J.; Derks, K.; Vaarwater, J.; Brands, T.; Verdijk, R.M.; Wiemer, E.A.C.; Mensink, H.W.; Pothof, J.; de Klein, A., et al. Aberrant MicroRNA Expression and Its Implications for Uveal Melanoma Metastasis. *Cancers (Basel)* **2019**, *11*, doi:10.3390/cancers11060815.

54. Falzone, L.; Romano, G.L.; Salemi, R.; Bucolo, C.; Tomasello, B.; Lupo, G.; Anfuso, C.D.; Spandidos, D.A.; Libra, M.; Candido, S. Prognostic significance of deregulated microRNAs in uveal melanomas. *Mol Med Rep* **2019**, *19*, 2599-2610, doi:10.3892/mmr.2019.9949.

55. Robertson, A.G.; Shih, J.; Yau, C.; Gibb, E.A.; Oba, J.; Mungall, K.L.; Hess, J.M.; Uzunangelov, V.; Walter, V.; Danilova, L., et al. Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma. *Cancer Cell* **2018**, *33*, 151, doi:10.1016/j.ccell.2017.12.013.

56. Catalanotto, C.; Cogoni, C.; Zardo, G. MicroRNA in Control of Gene Expression: An Overview of Nuclear Functions. *Int J Mol Sci* **2016**, *17*, doi:10.3390/ijms17101712.

57. He, L.; Hannon, G.J. MicroRNAs: small RNAs with a big role in gene regulation. *Nat Rev Genet* **2004**, *5*, 522-531, doi:10.1038/nrg1379.

58. Lee, R.C.; Feinbaum, R.L.; Ambros, V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. *Cell* **1993**, *75*, 843-854, doi:10.1016/0092-8674(93)90529-y.

59. Hammond, S.M. An overview of microRNAs. *Adv Drug Deliv Rev* **2015**, *87*, 3-14, doi:10.1016/j.addr.2015.05.001.

60. Reinhart, B.J.; Slack, F.J.; Basson, M.; Pasquinelli, A.E.; Bettinger, J.C.; Rougvie, A.E.; Horvitz, H.R.; Ruvkun, G. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. *Nature* **2000**, *403*, 901-906, doi:10.1038/35002607.

61. Pasquinelli, A.E.; Reinhart, B.J.; Slack, F.; Martindale, M.Q.; Kuroda, M.I.; Maller, B.; Hayward, D.C.; Ball, E.E.; Degnan, B.; Muller, P., et al. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. *Nature* **2000**, *408*, 86-89, doi:10.1038/35040556.

62. Griffiths-Jones, S.; Grocock, R.J.; van Dongen, S.; Bateman, A.; Enright, A.J. miRBase: microRNA sequences, targets and gene nomenclature. *Nucleic Acids Res* **2006**, *34*, D140-144, doi:10.1093/nar/gkj112.

63. John, B.; Enright, A.J.; Aravin, A.; Tuschl, T.; Sander, C.; Marks, D.S. Human MicroRNA targets. *PLoS Biol* **2004**, *2*, e363, doi:10.1371/journal.pbio.0020363.

64. Lewis, B.P.; Burge, C.B.; Bartel, D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell* **2005**, *120*, 15-20, doi:10.1016/j.cell.2004.12.035.

65. Shrivastava, S.; Steele, R.; Ray, R.; Ray, R.B. MicroRNAs: Role in Hepatitis C Virus pathogenesis. *Genes Dis* **2015**, *2*, 35-45, doi:10.1016/j.gendis.2015.01.001.

66. Shukla, G.C.; Singh, J.; Barik, S. MicroRNAs: Processing, Maturation, Target Recognition and Regulatory Functions. *Mol Cell Pharmacol* **2011**, *3*, 83-92.

67. Huntzinger, E.; Izaurralde, E. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. *Nat Rev Genet* **2011**, *12*, 99-110, doi:10.1038/nrg2936.

68. Ipsaro, J.J.; Joshua-Tor, L. From guide to target: molecular insights into eukaryotic RNA-interference machinery. *Nat Struct Mol Biol* **2015**, *22*, 20-28, doi:10.1038/nsmb.2931.

69. Vasudevan, S.; Tong, Y.; Steitz, J.A. Switching from repression to activation: microRNAs can up-regulate translation. *Science* **2007**, *318*, 1931-1934, doi:10.1126/science.1149460.

70. Vasudevan, S.; Steitz, J.A. AU-rich-element-mediated upregulation of translation by FXR1 and Argonaute 2. *Cell* **2007**, *128*, 1105-1118, doi:10.1016/j.cell.2007.01.038.

71. Garzon, R.; Marcucci, G.; Croce, C.M. Targeting microRNAs in cancer: rationale, strategies and challenges. *Nat Rev Drug Discov* **2010**, *9*, 775-789, doi:10.1038/nrd3179.

72. O'Brien, J.; Hayder, H.; Zayed, Y.; Peng, C. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. *Front Endocrinol (Lausanne)* **2018**, *9*, 402, doi:10.3389/fendo.2018.00402.

73. Jansson, M.D.; Lund, A.H. MicroRNA and cancer. *Mol Oncol* **2012**, *6*, 590-610, doi:10.1016/j.molonc.2012.09.006.

74. Lu, J.; Getz, G.; Miska, E.A.; Alvarez-Saavedra, E.; Lamb, J.; Peck, D.; Sweet-Cordero, A.; Ebert, B.L.; Mak, R.H.; Ferrando, A.A., et al. MicroRNA expression profiles classify human cancers. *Nature* **2005**, *435*, 834-838, doi:10.1038/nature03702.

75. Weber, J.A.; Baxter, D.H.; Zhang, S.; Huang, D.Y.; Huang, K.H.; Lee, M.J.; Galas, D.J.; Wang, K. The microRNA spectrum in 12 body fluids. *Clin Chem* **2010**, *56*, 1733-1741, doi:10.1373/clinchem.2010.147405.

76. Worley, L.A.; Long, M.D.; Onken, M.D.; Harbour, J.W. Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. *Melanoma Res* **2008**, *18*, 184-190, doi:10.1097/CMR.0b013e3282feeac6.

77. Onken, M.D.; Worley, L.A.; Ehlers, J.P.; Harbour, J.W. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. *Cancer Res* **2004**, *64*, 7205-7209, doi:10.1158/0008-5472.CAN-04-1750.

78. Radhakrishnan, A.; Badhrinarayanan, N.; Biswas, J.; Krishnakumar, S. Analysis of chromosomal aberration (1, 3, and 8) and association of microRNAs in uveal melanoma. *Mol Vis* **2009**, *15*, 2146-2154.

79. Wróblewska JP, L.M., Ustaszewski A, Kulcenty K, Ibbs M, Jagiello I, Suchorska WM, Marszalek A. The Potential Role of Selected miRNA in Uveal Melanoma Primary Tumors as Early Biomarkers of Disease Progression. *Genes (Basel)* **2020**, *11*, doi:doi:10.3390/genes11030271.

80. Larsen, A.C.; Holst, L.; Kaczkowski, B.; Andersen, M.T.; Manfe, V.; Siersma, V.D.; Kolko, M.; Kiilgaard, J.F.; Winther, O.; Prause, J.U., et al. MicroRNA expression analysis and Multiplex ligation-dependent probe amplification in metastatic and non-metastatic uveal melanoma. *Acta Ophthalmol* **2014**, *92*, 541-549, doi:10.1111/aos.12322.

81. Folberg, R.; Kadkol, S.S.; Frenkel, S.; Valyi-Nagy, K.; Jager, M.J.; Pe'er, J.; Maniotis, A.J. Authenticating cell lines in ophthalmic research laboratories. *Invest Ophthalmol Vis Sci* **2008**, *49*, 4697-4701, doi:10.1167/iovs.08-2324.

82. Angi, M.; Versluis, M.; Kalirai, H. Culturing Uveal Melanoma Cells. *Ocul Oncol Pathol* **2015**, *1*, 126-132, doi:10.1159/000370150.

83. Amirouchene-Angelozzi, N.; Nemati, F.; Gentien, D.; Nicolas, A.; Dumont, A.; Carita, G.; Camonis, J.; Desjardins, L.; Cassoux, N.; Piperno-Neumann, S., et al. Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target. *Mol Oncol* **2014**, *8*, 1508-1520, doi:10.1016/j.molonc.2014.06.004.

84. Peng, J.; Liu, H.; Liu, C. MiR-155 Promotes Uveal Melanoma Cell Proliferation and Invasion by Regulating NDFIP1 Expression. *Technol Cancer Res Treat* **2017**, *16*, 1160-1167, doi:10.1177/1533034617737923.

85. Zhou, J.; Jiang, J.; Wang, S.; Xia, X. Oncogenic role of microRNA20a in human uveal melanoma. *Mol Med Rep* **2016**, *14*, 1560-1566, doi:10.3892/mmr.2016.5433.

86. Liu, Y.; Huo, Y.; Wang, D.; Tai, Y.; Li, J.; Pang, D.; Zhang, Y.; Zhao, W.; Du, N.; Huang, Y. MiR-216a-5p/Hexokinase 2 axis regulates uveal melanoma growth through modulation of Warburg effect. *Biochem Biophys Res Commun* **2018**, *501*, 885-892, doi:10.1016/j.bbrc.2018.05.069.

87. Sun, L.; Wang, Q.; Gao, X.; Shi, D.; Mi, S.; Han, Q. MicroRNA-454 functions as an oncogene by regulating PTEN in uveal melanoma. *FEBS Lett* **2015**, *589*, 2791-2796, doi:10.1016/j.febslet.2015.08.007.

88. Ling, J.W.; Lu, P.R.; Zhang, Y.B.; Jiang, S.; Zhang, Z.C. miR-367 promotes uveal melanoma cell proliferation and migration by regulating PTEN. *Genet Mol Res* **2017**, *16*, doi:10.4238/gmr16039067.

89. Zhu, D.; He, X.; Duan, Y.; Chen, J.; Wang, J.; Sun, X.; Qian, H.; Feng, J.; Sun, W.; Xu, F., et al. Expression of microRNA-454 in TGF-beta1-stimulated hepatic stellate cells and in mouse livers infected with Schistosoma japonicum. *Parasit Vectors* **2014**, *7*, 148, doi:10.1186/1756-3305-7-148.

90. Chang, K.H.; Mestdagh, P.; Vandesompele, J.; Kerin, M.J.; Miller, N. MicroRNA expression profiling to identify and validate reference genes for relative quantification in colorectal cancer. *BMC Cancer* **2010**, *10*, 173, doi:10.1186/1471-2407-10-173.

91. Yan, D.; Dong, X.D.; Chen, X.; Yao, S.; Wang, L.; Wang, J.; Wang, C.; Hu, D.N.; Qu, J.; Tu, L. Role of microRNA-182 in posterior uveal melanoma: regulation of tumor development through MITF, BCL2 and cyclin D2. *PLoS One* **2012**, *7*, e40967, doi:10.1371/journal.pone.0040967.

92. Lu, Q.; Zhao, N.; Zha, G.; Wang, H.; Tong, Q.; Xin, S. LncRNA HOXA11-AS Exerts Oncogenic Functions by Repressing p21 and miR-124 in Uveal Melanoma. *DNA Cell Biol* **2017**, *36*, 837-844, doi:10.1089/dna.2017.3808.

93. Xia, Z.; Yang, C.; Yang, X.; Wu, S.; Feng, Z.; Qu, L.; Chen, X.; Liu, L.; Ma, Y. miR-652 Promotes Proliferation and Migration of Uveal Melanoma Cells by Targeting HOXA9. *Med Sci Monit* **2019**, *25*, 8722-8732, doi:10.12659/MSM.917099.

94. Zhang, L.; Liao, Y.; Tang, L. MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer. *J Exp Clin Cancer Res* **2019**, *38*, 53, doi:10.1186/s13046-019-1059-5.

95. Dong, F.; Lou, D. MicroRNA-34b/c suppresses uveal melanoma cell proliferation and migration through multiple targets. *Mol Vis* **2012**, *18*, 537-546.

96. Hou, Q.; Han, S.; Yang, L.; Chen, S.; Chen, J.; Ma, N.; Wang, C.; Tang, J.; Chen, X.; Chen, F., et al. The Interplay of MicroRNA-34a, LGR4, EMT-Associated Factors, and MMP2 in Regulating Uveal Melanoma Cells. *Invest Ophthalmol Vis Sci* **2019**, *60*, 4503-4510, doi:10.1167/iovs.18-26477.

97. Liu, J.; Ma, L.; Li, C.; Zhang, Z.; Yang, G.; Zhang, W. Tumor-targeting TRAIL expression mediated by miRNA response elements suppressed growth of uveal melanoma cells. *Mol Oncol* **2013**, *7*, 1043-1055, doi:10.1016/j.molonc.2013.08.003.

98. Amaro, A.; Croce, M.; Ferrini, S.; Barisione, G.; Gualco, M.; Perri, P.; Pfeffer, U.; Jager, M.J.; Coupland, S.E.; Mosci, C., et al. Potential Onco-Suppressive Role of miR122 and miR144 in Uveal Melanoma through ADAM10 and C-Met Inhibition. *Cancers (Basel)* **2020**, *12*, doi:10.3390/cancers12061468.

99. Chen, X.; Wang, J.; Shen, H.; Lu, J.; Li, C.; Hu, D.N.; Dong, X.D.; Yan, D.; Tu, L. Epigenetics, microRNAs, and carcinogenesis: functional role of microRNA-137 in uveal melanoma. *Invest Ophthalmol Vis Sci* **2011**, *52*, 1193-1199, doi:10.1167/iovs.10-5272.

100. Liu, N.; Sun, Q.; Chen, J.; Li, J.; Zeng, Y.; Zhai, S.; Li, P.; Wang, B.; Wang, X. MicroRNA-9 suppresses uveal melanoma cell migration and invasion through the NF-kappaB1 pathway. *Oncol Rep* **2012**, *28*, 961-968, doi:10.3892/or.2012.1905.

101. Chen, X.; He, D.; Dong, X.D.; Dong, F.; Wang, J.; Wang, L.; Tang, J.; Hu, D.N.; Yan, D.; Tu, L. MicroRNA-124a is epigenetically regulated and acts as a tumor suppressor by controlling multiple targets in uveal melanoma. *Invest Ophthalmol Vis Sci* **2013**, *54*, 2248-2256, doi:10.1167/iovs.12-10977.

102. Li, Y.; Huang, Q.; Shi, X.; Jin, X.; Shen, L.; Xu, X.; Wei, W. MicroRNA 145 may play an important role in uveal melanoma cell growth by potentially targeting insulin receptor substrate-1. *Chin Med J (Engl)* **2014**, *127*, 1410-1416.

103. Zhou, Y.; Zhang, L.; Fan, J.; Jia, R.; Song, X.; Xu, X.; Dai, L.; Zhuang, A.; Ge, S.; Fan, X. Let-7b overexpression leads to increased radiosensitivity of uveal melanoma cells. *Melanoma Res* **2015**, *25*, 119-126, doi:10.1097/CMR.0000000000000140.

104. Sun, L.; Bian, G.; Meng, Z.; Dang, G.; Shi, D.; Mi, S. MiR-144 Inhibits Uveal Melanoma Cell Proliferation and Invasion by Regulating c-Met Expression. *PLoS One* **2015**, *10*, e0124428, doi:10.1371/journal.pone.0124428.

105. Eedunuri, V.K.; Rajapakshe, K.; Fiskus, W.; Geng, C.; Chew, S.A.; Foley, C.; Shah, S.S.; Shou, J.; Mohamed, J.S.; Coarfa, C., et al. miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell Proliferation. *Mol Endocrinol* **2015**, *29*, 1170-1183, doi:10.1210/me.2015-1080.

106. Sun, L.; Sun, P.; Zhou, Q.Y.; Gao, X.; Han, Q. Long noncoding RNA MALAT1 promotes uveal melanoma cell growth and invasion by silencing of miR-140. *Am J Transl Res* **2016**, *8*, 3939-3946.

107. Zheng, X.; Tang, H.; Zhao, X.; Sun, Y.; Jiang, Y.; Liu, Y. Long non-coding RNA FTH1P3 facilitates uveal melanoma cell growth and invasion through miR-224-5p. *PLoS One* **2017**, *12*, e0184746, doi:10.1371/journal.pone.0184746.

108. Li, J.; Liu, X.; Li, C.; Wang, W. miR-224-5p inhibits proliferation, migration, and invasion by targeting PIK3R3/AKT3 in uveal melanoma. *J Cell Biochem* **2019**, *120*, 12412-12421, doi:10.1002/jcb.28507.

109. Peng, D.; Dong, J.; Zhao, Y.; Peng, X.; Tang, J.; Chen, X.; Wang, L.; Hu, D.N.; Reinach, P.S.; Qu, J., et al. miR-142-3p suppresses uveal melanoma by targeting CDC25C, TGFbetaR1, GNAQ, WASL, and RAC1. *Cancer Manag Res* **2019**, *11*, 4729-4742, doi:10.2147/CMAR.S206461.

110. Wu, S.; Chen, H.; Han, N.; Zhang, C.; Yan, H. Long Noncoding RNA PVT1 Silencing Prevents the Development of Uveal Melanoma by Impairing MicroRNA-17-3p-Dependent MDM2 Upregulation. *Invest Ophthalmol Vis Sci* **2019**, *60*, 4904-4914, doi:10.1167/iovs.19-27704.

111. Li, Y.; Luo, J.T.; Liu, Y.M.; Wei, W.B. miRNA-145/miRNA-205 inhibits proliferation and invasion of uveal melanoma cells by targeting NPR1/CDC42. *Int J Ophthalmol* **2020**, *13*, 718-724, doi:10.18240/ijo.2020.05.04.

112. Cunha Rola, A.; Taktak, A.; Eleuteri, A.; Kalirai, H.; Heimann, H.; Hussain, R.; Bonnett, L.J.; Hill, C.J.; Traynor, M.; Jager, M.J., et al. Multicenter External Validation of the Liverpool Uveal Melanoma Prognosticator Online: An OOG Collaborative Study. *Cancers (Basel)* **2020**, *12*, doi:10.3390/cancers12020477.

113. Bande Rodriguez, M.F.; Fernandez Marta, B.; Lago Baameiro, N.; Santiago-Varela, M.; Silva-Rodriguez, P.; Blanco-Teijeiro, M.J.; Pardo Perez, M.; Pineiro Ces, A. Blood Biomarkers of Uveal Melanoma: Current Perspectives. *Clin Ophthalmol* **2020**, *14*, 157-169, doi:10.2147/OPTH.S199064.

114. Triozzi, P.L.; Achberger, S.; Aldrich, W.; Singh, A.D.; Grane, R.; Borden, E.C. The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon. *J Transl Med* **2012**, *10*, 241, doi:10.1186/1479-5876-10-241.

115. Achberger, S.; Aldrich, W.; Tubbs, R.; Crabb, J.W.; Singh, A.D.; Triozzi, P.L. Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease. *Mol Immunol* **2014**, *58*, 182-186, doi:10.1016/j.molimm.2013.11.018.

116. Russo, A.; Caltabiano, R.; Longo, A.; Avitabile, T.; Franco, L.M.; Bonfiglio, V.; Puzzo, L.; Reibaldi, M. Increased Levels of miRNA-146a in Serum and Histologic Samples of Patients with Uveal Melanoma. *Front Pharmacol* **2016**, *7*, 424, doi:10.3389/fphar.2016.00424.

117. Stark, M.S.; Gray, E.S.; Isaacs, T.; Chen, F.K.; Millward, M.; McEvoy, A.; Zaenker, P.; Ziman, M.; Soyer, H.P.; Glasson, W.J., et al. A Panel of Circulating MicroRNAs Detects Uveal Melanoma With High Precision. *Transl Vis Sci Technol* **2019**, *8*, 12, doi:10.1167/tvst.8.6.12.

118. Sun, Y.; Liu, J. Potential of cancer cell-derived exosomes in clinical application: a review of recent research advances. *Clin Ther* **2014**, *36*, 863-872, doi:10.1016/j.clinthera.2014.04.018.

119. Ragusa, M.; Barbagallo, C.; Statello, L.; Caltabiano, R.; Russo, A.; Puzzo, L.; Avitabile, T.; Longo, A.; Toro, M.D.; Barbagallo, D., et al. miRNA profiling in vitreous humor, vitreal exosomes and serum from uveal melanoma patients: Pathological and diagnostic implications. *Cancer Biol Ther* **2015**, *16*, 1387-1396, doi:10.1080/15384047.2015.1046021.

120. Xin, X.; Zhang, Y.; Ling, F.; Wang, L.; Sheng, X.; Qin, L.; Zhao, X. Identification of a nine-miRNA signature for the prognosis of Uveal Melanoma. *Exp Eye Res* **2019**, *180*, 242-249, doi:10.1016/j.exer.2019.01.004.

121. Aughton K, S.H., Djirackor L, Coupland S.E, Kalirai H. Characterisation of uveal melanoma cell lines and primary tumor samples in 3D culture. *Trans Vis Sci Tech.* **2020**, *9*, doi:doi.org/10.1167/tvst.9.7.39.

|  |  |
| --- | --- |
| copyRight | © 2020 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |